 |
|
|
| |
100% SVR12 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS
|
| |
| |
Reported by Jules Levin
51st Annual Meeting of the European Association for the Study of the Liver
• Barcelona, Spain • 16 April 2016
Paul Y Kwo1, David L Wyles2, Stanley Wang3, Fred Poordad4, Edward Gane5, Benedict Maliakkal6, Mitchell L Shiffman7, Teresa I Ng3, Chih-Wei Lin3, Ran Liu3, Jens Kort3, Federico J Mensa3
1Indiana University School of Medicine, Indianapolis, Indiana, USA; 2University of California San Diego, La Jolla, California, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 5University of Auckland, Auckland, New Zealand; 6University of Rochester Medical Center, Rochester, New York, USA; 7Liver Institute of Virginia, Bon Secours Health System, Newport News and Richmond, VA, USA
|
| |
|
|
|
|
|
